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Among ten sociodemographic and lifestyle variables, smoking is 
strongly associated with biomarkers of acrylamide exposure in a 
representative sample of the US population1,,2,,3
Hubert W. Vesper, Maya R. Sternberg, Tunde Frame, and Christine M. Pfeiffer*
National Center for Environmental Health, CDC, Atlanta, GA
Abstract
Hemoglobin adducts of acrylamide (HbAA) and glycidamide (HbGA) have been measured as 
biomarkers of acrylamide exposure and metabolism in a nationally representative sample of the 
US population in the NHANES 2003–2004. We assessed the association of sociodemographic 
(age, sex, race-ethnicity, education, and income) and lifestyle variables (smoking, alcohol 
consumption, BMI, physical activity, and dietary supplement use) with these biomarkers in US 
adults (≥20 y). We used bivariate and multiple regression models and assessed the magnitude of an 
estimated change in biomarker level with change in a covariable for 2 biomarkers of acrylamide 
exposure.
Smoking was strongly and significantly correlated with HbAA and HbGA levels (rs=0.51 and 
0.42, respectively), with biomarker concentrations being 126% and 101% higher in smokers 
compared to nonsmokers after adjusting for sociodemographic and lifestyle covariates. Age was 
moderately and significantly correlated with both biomarkers (rs=−0.21 and −0.22, respectively). 
BMI (rs=−0.11) and alcohol consumption (rs=0.13) were weakly yet significantly correlated with 
HbAA levels only. The estimated percent change in biomarker concentration was ≤20% for all 
variables other than smoking after adjusting for sociodemographic and lifestyle covariates. Using 
multiple regression models, the sociodemographic variables explained 9% and 7%, while the 
sociodemographic and lifestyle variables together explained 46% and 25% of the variability in 
HbAA and HbGA, respectively, showing the importance of considering and adequately controlling 
for these variables in future studies. Our findings will be useful in the design and analysis of future 
studies that assess and evaluate exposure to acrylamide and its metabolism to glycidamide.
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INTRODUCTION
Acrylamide occurs in a wide range of food products that are commonly consumed by a large 
portion of the population. It is formed in food during frying or baking from the reaction of 
reducing sugars such as glucose with the amino acid asparagine via the Maillard reaction (1, 
2, 3). Among different food products, potato chips, French fries and some baked goods were 
found to contain high amounts of acrylamide (4, 5). Dietary intake is considered one major 
source of acrylamide exposure in the general population. Exposure to acrylamide is of 
concern, because acrylamide is a suspected human carcinogen and a potentially endocrine 
disrupting chemical (6, 7, 8, 9). These concerns initiated a wide range of research to assess 
intake, possible health risks, and to minimize acrylamide content in foods (10, 11, 12, 13).
Acrylamide is metabolized in the liver to its epoxide, glycidamide, which is primarily 
mediated by cytochrome P450 2E1 (14). Glycidamide forms DNA adducts and thus is 
considered genotoxic (15, 16, 17). Therefore, knowledge about exposure to acrylamide and 
its metabolite is important to assess and interpret potential health effects.
Adducts of acrylamide (HbAA)4 and glycidamide (HbGA) with hemoglobin, so called 
hemoglobin adducts, have been successfully used as biomarkers to assess acrylamide 
exposure in humans (18, 19, 20). These adducts reflect the time weighted exposure of 
acrylamide in a person over the past 4 mo.
CDC’s Second National Report on Biochemical Indicators of Diet and Nutrition in the US 
Population provides a descriptive analysis of the HbAA and HbGA levels of Americans by 
age, sex, and race-ethnicity for data from the NHANES 2003–2004. These analyses 
however, cannot explain why there are differences in these exposure biomarker levels among 
demographic subgroups (21).
Dietary intake and smoking are generally understood to be the 2 important determinants of 
HbAA and HbGA biomarker concentrations in blood. Several studies have investigated the 
relationship between dietary and smoking exposure and these biomarkers (20, 22, 24, 25, 26, 
27, 28). However, to our knowledge, no studies have systematically examined the 
association of a panel of sociodemographic and lifestyle variables on HbAA and HbGA 
levels in the US population. The objective of our analysis was to assess the association of 10 
selected sociodemographic and lifestyle variables with these biomarkers.
4Abbreviations used: HbAA, hemoglobin adduct of acrylamide; HbGA hemoglobin adduct of glycidamide; NCHS, National Center 
for Health Statistics; PIR, poverty income ratio.
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SUBJECTS AND METHODS
Survey design and participants
The NHANES collects cross-sectional data on the health and nutrition status of the civilian 
non-institutionalized US population (29). Participants in NHANES 2003–2004, aged ≥20 y 
(n = 4152) who had a stored blood specimen available for analysis of HbAA and HbGA 
constituted the study sample. All respondents gave their informed consent, and the 
NHANES protocol was reviewed and approved by the NCHS Research Ethics Review 
Board.
Laboratory methods
HbAA and HbGA were measured in EDTA whole blood as described previously (27, 30). 
The detection limits for HbAA and HbGA adducts were 3 and 4 pmol/g of Hb, respectively. 
The inter-day imprecision (n = 20 d) of this method, expressed as percent CV, was on 
average 13% for HbAA and 19% for HbGA, determined with 3 blood pools.
Sociodemographic and lifestyle variables
For bivariate analyses, we categorized the variables as follows: age (20–39 y, 40–59 y, and 
≥60 y); race-ethnicity (non-Hispanic white [NHW], non-Hispanic black [NHB], and 
Mexican American [MA]); education (<high school, high school, and >high school); family 
poverty income ratio (PIR; 0–1.85 [low], >1.85–3.5 [medium], and >3.5 [high], (31)); 
smoking status (serum cotinine ≤10 μg/L [nonsmoker], >10 μg/L [smoker], (32)); alcohol 
consumption (average daily number of “standard” drinks [1 drink ≈ 15 g ethanol ]; no 
drinks, <1 drink (not 0), 1-<2 drinks, ≥2 drinks); BMI (kg/m2) (<18.5 [underweight], ≥18.5 
and <25.0 [normal], ≥25.0 and <30.0 [overweight], ≥30.0 [obese], (33)); physical activity 
(calculated as total metabolic equivalent task (MET)-min/wk from self-reported leisure time 
physical activities; no leisure time physical activities, 0–<500, 500–<1000, ≥1000 MET-min/
wk); supplement use (reported taking a dietary supplement within the past 30 d; yes [user], 
no [non-user]).
Statistical analyses
As we used the same statistical methods for the series of papers presented in this 
supplement, the reader is referred to Sternberg et al. (34) for a detailed description of the 
methods and for a discussion of compromises taken in developing the multiple regression 
model due to the limited degrees of freedom, such as the number of covariates considered, 
the chosen form of continuous covariates, and the consideration of interactions between 
covariates. Bivariate associations for categorical variables were assessed by calculating the 
geometric means and 95% CI for each category and Spearman correlations for selected 
continuous variables. Linear regression analyses were used to assess the confounding effects 
and to determine whether statistical significance persisted after adjusting for differences in 
key variables. HbAA and HbGA data were log transformed based on the distribution of the 
biomarker. The covariates were arranged into 2 chunks: sociodemographic variables (age, 
sex, race-ethnicity, education level, and PIR) and lifestyle variables (smoking, alcohol 
consumption, BMI, physical activity, and dietary supplement use) and entered hierarchically. 
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We summarized the results of each model and showed the magnitude of association by 
presenting the percent change in biomarker concentrations with change in each covariate 
holding all other remaining covariates constant for each model. All estimates were weighted 
to account for the unequal probabilities of selection and adjustment for non-response. Two-
sided P-values were flagged as statistically significant if P <0.05.
RESULTS
HbAA and HbGA data were available for 4093 and 4152 NHANES participants, 
respectively. The study population was estimated to consist of 48% men and 71% 
nonsmokers. The proportion of NHW, NHB and MA was 72%, 11% and 8%, respectively 
(Table 1).
Spearman correlation coefficients showed that smoking was strongly and significantly 
correlated with HbAA (rs = 0.51) and HbGA (rs = 0.42), while other variables showed no or 
only weak correlations (|rs| ≤0.2, P <0.05) (Table 2). Using bivariate methods (model 1), all 
sociodemographic variables were significantly but weakly associated with HbAA and all but 
sex and PIR were significantly but weakly associated with HbGA (Table 3). Values for both 
biomarkers were lower among persons with higher age, educational level and PIR. NHB had 
higher HbAA and lower HbGA values compared to the other 2 race-ethnic groups and men 
had higher HbAA values compared to women. Most lifestyle variables except for smoking 
were either weakly or not associated with biomarkers of acrylamide exposure (Table 4). 
Smoking was associated with at least 100% higher hemoglobin adduct values compared to 
not smoking; supplement use with ~20% higher values for both biomarkers; and increasing 
consumption of alcohol with higher levels of HbAA. Physical activity was not associated 
with either marker of acrylamide exposure, while higher BMI was associated with lower 
levels of HbAA only.
Using multiple regression models, the sociodemographic variables (model 2) explained 9% 
of the variability in biomarker values for HbAA and 7% for HbGA (Supplemental Table 1). 
Together, the sociodemographic and lifestyle variables (model 3) explained 46% and 25% of 
the HbAA and HbGA variability, respectively. In all models, age, smoking, supplement use, 
and BMI remained significantly associated with HbAA levels after adjusting for 
sociodemographic and lifestyle variables (Supplemental Table 1). Age, smoking, and race 
(NHB vs. NHW only) remained significantly associated with HbGA levels. Sex and alcohol 
consumption were significantly associated with HbGA after controlling for both 
sociodemographic and lifestyle variables.
Because the log transformations may obscure the interpretation of the beta coefficients, we 
estimated the percent change in biomarker levels associated with each covariable (Fig. 1 and 
Supplemental Table 2). Smoking had a strong association with both biomarkers, with 
estimated biomarker levels in smokers being ~100% higher for HbGA and ~130% higher for 
HbAA compared to nonsmokers after adjusting for sociodemographic and lifestyle 
variables. All other estimated percent changes were comparatively moderate (≤20%) and 
generally not consistent between HbAA and HbGA, except for age which was associated 
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with slightly but significantly lower HbAA (3%) and HbGA (6%) values with every 10 y 
increase (model 3).
DISCUSSION
Among the 10 sociodemographic and lifestyle variables investigated in this representative 
sample of US adults, smoking showed a strong association with both biomarkers of 
acrylamide exposures and remained a significant variable in all regression models. Smokers 
had at least twice the HbAA and HbGA levels compared to nonsmokers which is consistent 
with other studies (27, 35). Among the sociodemographic variables, we found age to be 
significantly negatively associated with HbAA and HbGA levels in all models, suggesting 
that acrylamide exposure as well as metabolism may change with age.
In our full regression model, race (NHB vs. NHW only) and sex were significant correlates 
for HbGA but not for HbAA, suggesting differences in acrylamide metabolism rather than in 
acrylamide exposure. Different polymorphisms for CYP 2E1 and their impact on acrylamide 
metabolism have been described (36, 37, 38). However, no information is available about the 
occurrence and frequency of these polymorphisms in this study population. Similarly, sex 
differences in the pharmacologic activity of CYP 2E1 seem to exist (39, 40), but the impact 
of these differences on acrylamide is not fully understood.
Our analysis found that BMI was significantly negatively associated with HbAA levels, 
which is consistent with a previous study (35). The reason for the negative association is not 
fully understood and requires further investigation.
Alcohol consumption was significantly negatively associated with HbGA values in our 
analysis only after adjusting for sociodemographic and lifestyle variables, which appears 
consistent with observations in other study populations (30, 41). Alcohol induces CYP 2E1, 
which metabolizes alcohol as well as acrylamide (42). The negative association could be 
explained with a competitive effect of alcohol and acrylamide as substrate.
While sociodemographic variables alone explained only 9% of the variability in HbAA and 
7% for HbGA, the full regression model 3 which also included lifestyle variables explained 
46% of HbAA and 25% of HbGA variability. These findings seem consistent with a 
previous study that investigated the association of food intake on biomarker levels using data 
from the same NHANES survey, but included children as well (43).
To our knowledge, this is the first study that examined the association and cumulative effects 
of demographic, socioeconomic, and lifestyle variables on HbAA and HbGA levels. By 
applying a systematic modeling approach, we were able to assess the magnitude of an 
estimated change in biomarker level with change in covariable across biomarkers. 
Furthermore, the findings for the acrylamide biomarkers can also be compared to findings 
for other classes of diet and nutrition biomarkers reported in accompanying papers in this 
supplement. The use of a chunk test in our modeling approach maintains the interpretation 
of the beta coefficients and P-values and therefore is less likely to yield false positive 
findings that are associated with automatic variable selection methods like backwards 
elimination.
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The limitations in our study are the lack of testing for interactions between individual 
variables, which was not performed due to limitations in degrees of freedom. We did not 
study biological variables or how dietary intake is associated with HbAA and HbGA or 
interacts with variables included in our analysis. However, dietary acrylamide intake 
estimates were found to correlate only weakly with HbAA and HbGA (20, 22, 25). This 
could be explained with the high variability in acrylamide content within food groups, the 
different exposure periods covered by food intake questionnaires and biomarkers, and 
incomplete acrylamide data in foods. Our analysis was designed to examine associations of 
HbAA and HbGA with selected variables after adjusting for sociodemographic and lifestyle 
variables. In this context, acrylamide intake would be considered an outcome variable as 
opposed to a covariate.
In summary, we conclude that smoking, age and BMI were the 3 variables that were related 
with HbAA and that smoking, race and alcohol consumption were important correlates for 
HbGA. The results from this descriptive modeling analysis will help future data analyses 
that set out to build predictive models to answer specific research questions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Estimated change in hemoglobin adduct of acrylamide and glycidamide with change in 
sociodemographic and lifestyle variables for adults ≥20 y, NHANES 2003–2004
Model 1 represents simple linear regression, model 2 represents multiple linear regression 
with sociodemographic factors, and model 3 represents multiple linear regression with 
sociodemographic and lifestyle factors; changes derived from a linear regression model 
while holding any other variables in the model constant; asterisk accompanying the percent 
change indicates significance (P <0.05).
NHB, non-Hispanic black; NHW, non-Hispanic white; HS, high school; PIR, poverty 
income ratio.
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Table 1
Descriptive information for the adult US population aged ≥20 y by sociodemographic and lifestyle variables, 
NHANES 2003–2004
Variable Category Estimate1 Sample size2
Acrylamide hemoglobin adduct Glycidamide hemoglobin adduct
Age, y 20–39 38.8 1406 1446
40–59 38.5 1164 1177
≥60 22.7 1523 1529
Sex Male 48.0 1974 2008
Female 52.1 2119 2144
Race-ethnicity Mexican American 7.76 862 867
Non-Hispanic black 11.2 748 787
Non-Hispanic white 72.1 2182 2203
Education <High school 30 1213 1229
High school 25 1039 1047
>High school 45 1834 1870
PIR3 Low (0–1.85) 31.4 1664 1702
Middle (>1.85–3.5) 27.6 1012 1016
High (>3.5) 41.1 1192 1207
Supplement use4 No 70.2 2106 2183
Yes 29.8 1924 1960
Smoking status5 No 71.2 2987 3013
Yes 28.9 1067 1098
Alcohol consumption6 No drinks 30.6 1413 1596
<1 (not 0) 56.6 1954 909
1–<2 7.6 237 493
≥2 5.2 184 989
BMI7 Underweight 1.73 57 56
Normal weight 32.0 1217 1225
Overweight 34.1 1431 1438
Obese 32.2 1303 1347
Physical activity8 None reported 33.0 1588 1596
0–<500 25.0 894 909
500–<1000 13.6 483 493
≥1000 28.4 964 989
1
Estimates provided are percent (%)
2Values represent unweighted sample sizes
3
PIR, family poverty income ratio; low: 0–1.85; medium: >1.85–3.5; high: >3.5
4
“Supplement user” defined as participant who reported taking a dietary supplement within the past 30 d
6Alcohol consumption: calculated as average daily number of “standard” drinks [(quantity × frequency)/365.25]; 1 drink ≈ 15 g ethanol
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7
BMI (kg/m2) definitions: underweight: <18.5; normal weight: 18.5–<25; overweight: 25–<30; and obese: ≥30
8
Physical activity: calculated as total metabolic equivalent task (MET)-min/wk from self-reported leisure time physical activities
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Table 2
Spearman correlation coefficients describing bivariate associations between hemoglobin adducts of acrylamide 
and glycidamide and selected continuous sociodemographic and lifestyle variables for adults ≥20 y, NHANES 
2003–2004
Variable Acrylamide hemoglobin adduct Glycidamide hemoglobin adduct
Age
−0.21* −0.22*
PIR1 −0.06* −0.07*
Smoking 0.51* 0.42*
Alcohol consumption 0.13* −0.03
BMI
−0.11* 0.00
Physical activity 0.02 −0.04
*Significant correlation; P <0.05
1
PIR, family poverty income ratio
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Table 3
Unadjusted biomarker levels by sociodemographic variable categories for adults ≥20 y, NHANES 2003–20041
Variable Acrylamide hemoglobin adduct
pmol/g Hb
Glycidamide hemoglobin adduct
pmol/g Hb
Age, y 20–39 68.5 (64.1 – 73.3) 65.0 (61.4 – 68.9)
40–59 64.0 (59.9 – 68.4) 60.1 (56.8 – 63.5)
≥60 50.1 (47.9 – 52.3) 45.5 (42.8 – 48.3)
 P-value2 <0.0001 <0.0001
 r2 (%)3 4 4
Sex Men 65.9 (61.5 – 70.5) 58.6 (55.7 – 61.7)
Women 58.9 (55.7 – 62.2) 57.8 (54.4 – 61.4)
 P-value <0.0001 0.54
 r2 (%) 1 < 1
Race-ethnicity4 MA 62.7 (59.3 – 66.3) 62.9 (59.0 – 67.0)
NHB 66.5 (58.0 – 76.2) 52.9 (49.4 – 56.7)
NHW 63.1 (59.2 – 67.3) 60.0 (56.1 – 64.1)
 P-value <0.0001 <0.0001
 r2 (%) 2 1
Education <High school 65.0 (58.9 – 71.6) 59.0 (54.4 – 63.9)
High school 69.0 (62.7 – 75.9) 64.3 (59.6 – 69.4)
>High school 58.1 (55.1 – 61.3) 55.2 (52.1 – 58.5)
 P-value 0.0004 0.0009
 r2 (%) 2 1
PIR5 Low 66.7 (62.7 – 70.9) 60.3 (56.9 – 63.9)
Medium 61.5 (57.7 – 65.6) 59.2 (56.8 – 61.8)
High 59.2 (55.9 – 62.8) 56.4 (53.3 – 59.6)
 P-value <0.0001 0.06
 r2 (%) 1 < 1
1Values represent geometric means (95% CI)
2P-value based on Wald F test, which tests whether at least 1 of the means across the categories is significantly different
3
r2 based on model 1, simple linear regression, using categories as shown
4
MA, Mexican American; NHB, non-Hispanic black; NHW, non-Hispanic white
5
PIR, family poverty income ratio; low: 0–1.85; medium: >1.85–3.5; high: >3.5
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Table 4
Unadjusted biomarker levels by lifestyle variable categories for adults ≥20 y, NHANES 2003–20041
Variable Acrylamide hemoglobin adduct
pmol/g Hb
Glycidamide hemoglobin adduct
pmol/g Hb
Supplement use2 No 57.4 (54.8 – 60.1) 54.5 (51.5 – 57.5)
Yes 68.4 (63.3 – 73.9) 63.1 (59.9 – 66.4)
 P-value3 <0.0001 <0.0001
 r2 (%)4 2 1
Smoking5 No 48.2 (46.4 – 50.1) 47.7 (45.5 – 49.9)
Yes 114 (104 – 125) 93.7 (86.7 – 101)
 P-value <0.0001 <0.0001
 r2 (%) 42 20
Alcohol consumption6 No drinks 54.4 (50.7 – 58.4) 54.9 (51.4 – 58.7)
<1 (not 0) 63.0 (59.4 – 66.7) 59.7 (56.5 – 63.0)
1–<2 79.1 (71.4 – 87.6) 64.2 (56.2 – 73.4)
≥2 84.4 (70.1 – 102) 55.8 (45.9 – 67.9)
 P-value <0.0001 0.0245
 r2 (%) 4 4
BMI7 Underweight 80.4 (58.5 – 110) 55.7 (39.2 – 79.0)
Normal 67.4 (62.8 – 72.3) 59.1 (55.4 – 63.0)
Overweight 60.9 (56.9 – 65.1) 57.3 (52.9 – 62.1)
Obese 58.1 (54.5 – 61.9) 58.7 (55.7 – 61.7)
 P-value 0.0002 0.89
 r2 (%) 1 0
Physical activity8 None reported 64.1 (59.2 – 69.5) 59.5 (55.2 – 64.2)
0–<500 61.5 (58.2 – 64.9) 60.4 (56.6 – 64.4)
500–<1000 58.8 (54.0 – 63.9) 55.2 (49.7 – 61.4)
≥1000 61.8 (57.9 – 66.1) 56.5 (52.8 – 60.5)
 P-value 0.23 0.06
 r2 (%) < 1 < 1
1Values represent geometric means (95% CI)
2
“Supplement user” defined as participant who reported taking any dietary supplement within the past 30 d
3P-value based on Wald F test, which tests whether at least one of the means across the categories is significantly different
4
r2 based on model 1, simple linear regression, using categories as shown
5
“Smoker” defined by serum cotinine concentration >10 μg/L; ≤10 μg/L defined as “nonsmoker”
6Alcohol consumption (drinks/d): calculated as average daily number of “standard” drinks [(quantity × frequency)/365.25]; 1 drink ≈ 15 g ethanol
7
BMI (kg/m2) definitions: underweight: <18.5; normal weight: 18.5–<25; overweight: 25–<30; and obese: ≥30
8
Physical activity: calculated as total metabolic equivalent task (MET)-min/wk from self-reported leisure time physical activities
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